



Healionics Partners with UW, Receives Washington Technology Center (WTC) Award for Infection-Reducing Biotechnology

Seattle, WA (July 15, 2010) — Healionics and the Department of Medicine at the University of Washington have received an award from Washington Technology Center to continue a project that can reduce infection from skin-breaching devices such as catheters.

The University of Washington will receive \$82,500 in Phase III state funding from WTC for research and technology development. Dr. Philip Fleckman, Professor of Medicine in Dermatology, will serve as the principal investigator. The commercialization of this technology can result in Healionics capturing a significant part of a \$100-200 million market.

“Thanks to the support from Washington Technology Center, the outcome of this Phase III proposal will help us move towards generating more local high tech jobs as device manufacturing develops,” said Dr. Max Maginness, Chief Technology Officer of Healionics.

More information about the WTC and this year’s award can be found at <http://news.watechcenter.org/2010/07/washington-technology-center-awards.html>

About Healionics Corporation

Healionics is a privately held biomaterials company whose mission is to be the leading provider of tissue regeneration and device biointegration solutions to healthcare manufacturers. The Company’s flagship STAR® biomaterial is specifically engineered to enhance biointegration and promote healing of long-term implanted medical devices. Healionics Corporation is headquartered in Seattle, Washington. For more information, please visit <http://www.healionics.com>.

###

Contact:
Julie Rathbun
Rathbun Communications, Inc.
(206) 769-9219
Julie@rathbuncomm.com